Pune Media
Leading the news curation and publishing for the people of Pune

Meet man who works for Rs 2,71,000 crore company, son of India’s second richest pharma billionaire

He joined the company in 2006 as a product manager.

Aalok Shanghvi is the Executive Director of Sun Pharma, an Indian multinational pharmaceutical company headquartered in Mumbai. He is the eldest child of Dilip Shanghvi, Managing Director of Sun Pharma. 

Aalok joined the company in 2006 as a product manager. Since then, he has handled various roles in Marketing, R&D and Project Management among other things. In 2010, he headed Bangladesh and by 2014, he took over the Emerging Markets business, which is spread across 80 countries covering Africa, the Middle East other regions.

He holds an undergraduate degree in Cellular and Molecular Biology from the University of Michigan. His father Dilip Shanghvi is India’s second richest pharma billionaire with a real-time net worth of USD 18.5 billion as of September 9, 2023, according to Forbes. This is around Rs 1,53,780 crore today.

Sun Pharma has a market capitalisation of Rs 2,71,000 crore company as of September 8, 2023. The share price of the company was Rs 1,129.15 on Friday. Aalok also took charge of Global Generic R&D, Global Generic Business Development and API.

The company was founded by his father Dilip Shanghvi in 1983 in Vapi, Gujarat. It is the largest pharmaceutical company in India and the fourth-largest speciality generic pharmaceutical company in the world. Dilip grew his company through a series of acquisitions, the biggest of which was the 2014 purchase of scandal-tainted rival Ranbaxy Laboratories for USD 4 billion.

READ | This man started Rs 24,00,000 crore business empire with just Rs 21,000

Images are for reference only.Images and contents gathered automatic from google or 3rd party sources.All rights on the images and contents are with their legal original owners.

Aggregated From –

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More